Big Pharma6 years ago
SOYLENT GREEN: Big Pharma Giant GlaxoSmithKline Spends $300 Million For Access To DNA Database Of Genealogy Tracking Company 23AndMe
Last week’s announcement that GlaxoSmithKline is gaining exclusive rights to mine the 23andMe customer database for drug targets should come as no surprise.
